Ik‐Joo Chung

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu et al. · The Lancet Oncology · 2022 · 712 citations · Full text

Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma

Deok‐Hwan Yang, Jung‐Joon Min, Ho‐Chun Song et al. · European Journal of Cancer · 2011 · 87 citations

Lymphoid Neoplasia, Surgical Oncology, Oncologic Imaging +7

Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Călin Cainap, Shukui Qin, Wen‐Tsung Huang et al. · Journal of Clinical Oncology · 2013 · 82 citations

Vascular Disease, Advanced Cpa Hcc, Pathology +25

Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer

Jun‐Eul Hwang, Hana Kim, Dae‐Eun Kim et al. · BMC Cancer · 2011 · 81 citations · Full text

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

Jun‐Eul Hwang, Ji-Yun Hong, Ka-Rham Kim et al. · BMC Cancer · 2013 · 59 citations · Full text